In step 3, we excluded four patients due to terminal illness (severe dementia, terminal cancer) or death before visit and an additional nine patients who were no longer suitable for sacubitril-valsartan (New York Heart Association Class I, or NT-proBNP less than 600 ng/L). The gene discussed is NPPB; the disease is dementia.